INTRODUCTION
Inflammatory and malignant diseases in humans are currently associated with elevated plasma levels of cytokines [1] . Previous studies reported a significant reduction in serum cholesterol levels during episodes of acute myocardial infarction (AMI) [2] , as a result of major surgery, and during acute infections [3] . The significant inverse correlation between cholesterol and interleukin-6 (IL-6) [4] might suggest an active role of IL-6 in changes in serum lipoprotein levels. This effect on serum total cholesterol (TC) was also observed after systemic infusion of cytokines in animal models [5] . Cytokines may modulate cholesterol and lipoprotein serum levels by stimulating apolipoprotein-lipolytic enzymes and lipoprotein receptor gene expression and secretion [6, 7] . Recent findings showed up-regulation of low-density lipoprotein receptor (LDLR) gene expression induced by IL-6 in hepatic cells with the consequent reduction of low-density lipoprotein (LDL) plasma levels [8] . The high plasma level of TC, especially LDL, represents one of the major cardiovascular risk factors. An association between oxidized LDL (ox-LDL) and atherogenesis was first suggested by experiments showing that ox-LDL caused injury to endothelial cells [9] and was further supported by studies showing a protective effect of antioxidants against atherosclerosis progression [10] . Hypercholesterolemia is associated with production of free radicals and lipoperoxides, and it is currently recognized to induce phenotypic changes in microvascular cells [11, 12] . In addition, elevated plasma levels of isoprostanes, products of lipid peroxidation, are associated with coronary artery disease (CAD) and inflammation [13] , and elevated plasma levels of malondialdehyde (MDA)-modified LDL are associated with plaque instability [14] . Oxidized lipoprotein receptor-1 (LOX-1), a 52-kD type II transmembrane receptor for ox-LDL belonging to the C-type lectin family, is present primarily on endothelial cells [15] . Previous studies demonstrated that ox-LDL uptake through this receptor induces endothelial dysfunction, generates superoxide anions, reduces nitric oxide production, and activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) [16, 17] . This receptor is expressed in the aorta of hypertensive, diabetic and hyperlipidemic animals [18] , and it is up-regulated in early human atherosclerotic lesions [19] . These results suggest that LOX-1 plays an important role in atherogenesis, by internalizing and degrading ox-LDL, and in inflammatory responses in vivo, raising cellular ox-LDL uptake [20] . The endothelial activation and dysfunction induced by ox-LDL is a key event in the pathogenesis of inflammation and atherosclerosis. Cell death represents one of the most important toxic mechanisms related to the high concentration of ox-LDL and may occur either in the form of necrosis or apoptosis [21] . LOX-1 is a new type of receptor, the principal for ox-LDL, and some studies have emphasized its mediation in the induction of apoptosis in human coronary artery cells [22] . Our findings showed a positive correlation between serum LOX-1 and cytokine levels in patients affected by CAD, but in patients with more severe conditions the ox-LDL serum concentrations decreased, reverting to control values [23] ; the reduced levels of ox-LDL could be due to increased uptake of ox-LDL by LOX-1, receptors highly expressed in this group. Peroxidation of lipids leads to the production of isoprostanes, a recently discovered series of bioactive prostaglandin F2 (PGF2)-like compounds. Isoprostanes are produced independently of the cyclooxygenase enzymes via arachidonic acid peroxidation, catalyzed by free radicals. 8-Isoprostane is a product of lipid peroxidation that has been shown to have biological activity [24, 25] , generated in vivo, is ubiquitous and abundant, and induces vasoconstriction [26] [27] [28] [29] . Evidence suggests that 8-isoprostane may act in part through the vascular thromboxane A 2 (TXA 2 ) receptor [30] ; whether 8-isoprostane interferes with IL-6 synthesis in microvascular endothelium is still unknown. The purpose of this study was to determine whether plasma LDL and ox-LDL could induce the production of IL-6 and whether this inflammatory cytokine was able to modulate the expression of LOX-1 and LDLR. We investigated IL-6 expression and production by treating human microvascular endothelial cells-1 (HMEC-1) with increasing concentrations of human native LDL, ox-LDL and 8-isoprostane. Additionally, to elucidate whether IL-6 affects plasma LDL and ox-LDL levels, we explored the effect of increasing doses of IL-6 on LDLR and LOX-1 gene expression in HMEC-1.
MATERIALS AND METHODS

Cell cultures
HMEC-1 cells were obtained from the National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control & Prevention (CDC) (Atlanta, GA). HMEC-1 cells retain morphological, phenotypic and functional characteristics of normal human microvascular endothelial cells [31] . These cells were currently cultured in 199 medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Inc., Carlsbad, CA), 1% glutamine, 1% antibiotics (Sigma-Aldrich, St Louis, MO), 1% endothelial growth factor (EGF) (Sigma), and 0.5% hydrocortisone (Sigma), were plated on a six-well plate and grown until confluence. Before each treatment, HMEC-1 were preincubated for 48 h with M 199 without phenol red, containing antibiotics and 1% FBS. Then, cells were treated for 24 h with 50, 100, and 200 µg of apoB/ml of both native and ox-LDL. Cell viability was assessed by trypan blue dye exclusion assay.
LDL isolation and oxidation
Blood samples (10 ml) were collected in ethylenediaminetetraacetic acid (EDTA) Vacutainer tubes (1 mg/ml) and immediately centrifuged at 3,000 rpm at 4°C for 10 minutes. LDLs (d = 1.019-1.063) were isolated by ultracentrifugation at 42,000 rpm at 4°C (OPTIMA L-90 K, Beckman, CA, USA) in NaBr solution with EDTA. All solutions were degassed and samples were kept at 4°C in a dark environment. To remove EDTA, the LDL fraction was gel-filtered on a Sephadex column (Econo-Pac 10 DG columns; Bio-Rad) and eluted in PBS buffer (1 mol/l, pH = 7.4). Copper-oxidized LDL was prepared as described previously [32, 11] . The extent of oxidation was estimated by measuring thiobarbituric acid-reactive substances expressed as nmol of MDA per mg of LDL protein according to the Esterbauer and Cheeseman method [33] . Native LDL exposed to 10 µM CuSO 4 for 6 h at 37° led to mildly ox-LDL containing 5.82 nmol of MDA per mg of apoB. After incubation of native LDL for 12 h at 37°C with CuSO 4 , a solution of more strongly ox-LDL was obtained, whose MDA concentration was 12.75 nmol per mg of apoB. Immediately when cells reached 80% confluence they were treated with 50, 100 and 200 µg apoB/ml of native LDL and ox-LDL solutions. The same experiment was repeated using 10 -6 M of SQ29.548, a TXA 2 receptor antagonist (Cayman, Ann Arbor MI, USA). 
RNA extraction and quantitative real-time PCR
Total RNA was isolated from HMEC-1 using PureZOL RNA isolation reagent (Bio-Rad, CA) and then was reverse-transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, CA) following the manufacturer's protocol. Quantitative real-time PCR was performed using SsoFastTM EvaGreen Supermix (Bio-Rad, CA) in the StepOnePlusTM Real-Time PCR System (ABI Applied Biosystems, Foster City, CA), software version v.2.2.2. The gene-specific primers used were designed using Beacon Designer Software (Premier Biosoft International, USA) and were as follows: IL-6 (forward primer 5′-AAAGCAGCAAAGAGGCAC-3′, reverse primer 5′-TTCACCAGGCAA GTCTCC-3′), LDLR (forward primer 5'-CAACCACCCGACCTGTTC-3', reverse primer 5'-CATTTCCTCTGCCAGCAAC-3'), LOX-1 (forward primer 5'-CCTTTGCCTGGGATTAGTAGT-3', reverse primer 5'-GCTCTTGT GTTAGGAGGTCA-3'), and β-actin (forward primer 5'-GAGATGCGT-TGTTACAGGAAG-3', reverse primer 5'-TGGACTTGGGAGAGGACT-3'). PCR reaction was performed in a 20 µl reaction volume and consisted of an initial denaturation step at 95°C for 2 min, followed by 40 amplification cycles at 95°C for 5 s and 62°C for 15 s. Melt-curve analysis was performed immediately after the amplification protocol under the following conditions: 15 s denaturation at 95°C, 1 min annealing at 60°C, followed by a step of incremental temperature increase of 0.3°C from 60°C to 95°C.
The expression level of genes was calculated by using the 2 −ΔΔCT relative quantification method [34] with β-actin as an internal reference. Both target and reference (β-actin) genes were amplified in separate wells in triplicate and in three different experiments.
Analytical methods
Hs-IL-6 was quantified using sandwich ELISA kits (Biosource International, California, USA) whose inter-assay coefficients of variation were 7.8% and 8.5% respectively.
Statistical analysis
Data are expressed as mean ± SEM. Differences between cell supernatant IL-6 levels were tested using one-way ANOVA with Dunnett's post-hoc test and twoway ANOVA test. LDLR and LOX-1 gene expression differences were evaluated by one-way ANOVA with Dunnett's post-hoc test. A p-value lower than 0.05 was considered statistically significant. All statistical procedures were performed with GraphPad Software, CA, USA.
RESULTS
All concentrations of ox-LDL or IL-6 used in the experiments separately did not induce any toxicity to the cells, cell viability was always greater than 95% as determined by trypan blue exclusion (data not shown).
ELISA
Native LDL and ox-LDL treatments
When HMEC-1 cells were exposed to several native LDL concentrations, IL-6 levels in cell supernatant were significantly increased only after 200 µg apoB/ml treatment without SQ29.548 (p < 0.05, Fig. 1A ). After HMEC-1 incubation with 200 µg of apo-B/ml of mildly ox-LDL, showing an MDA concentration of 5.82 nmol per mg of apo-B, the mean of IL-6 concentration in cell medium exhibited a significant dose-dependent increase with and without SQ29.548 ( Figs 1A, 1B) . Compared with baseline values, IL-6 levels showed a progressive change in response to increasing concentrations of ox-LDL and became statistically significant at 100 and 200 µg/ml (p < 0.01 at 200 µg/ml Fig. 1A ; p < 0.05, p < 0.01 at 100 and 200 µg/ml, respectively, Fig. 1B ). After HMEC-1 treatment with strong ox-LDL, showing an MDA concentration of 12.75 nmol per mg of apo-B, IL-6 medium concentrations were evaluated. The production of IL-6 in the medium of cells exposed to increasing concentrations of ox-LDL with and without SQ29.548 is shown in Figs 1A , 1B (p < 0.001 at 50, 100 and 200 µg of apo-B/ml compared to control, Fig. 1A ; p < 0.001 at 50 and 200 µg of apo-B/ml and p < 0.01 at 100 µg of apo-B/ml compared to control, Fig. 1B) . IL-6 levels were related not only to LDL concentration, but also to LDL oxidation degree. These two factors showed a positive interaction (p < 0.001 by ANOVA). The addition of SQ29.548, the TXA 2 receptor antagonist, did not induce any statistical difference in medium IL-6 levels. The stimulating effect of LDL on IL-6 accumulation in endothelial cells was only marginally modified by TXA 2 receptor blockade (-10%, p = ns).
8-Isoprostane treatment
HMEC-1 exposed 24 h to increasing concentrations of 8-isoprostane (0, 10 -11 ,
10
-10 , 10 -9 and 10 -8 M) in the presence and absence of the TXA 2 receptor antagonist SQ29.548 [12] did not show any significant difference compared to the basal condition (Fig. 2) . 
Quantitative real-time PCR
Effect of ox-LDL treatment on IL-6 expression
Effect of IL-6 treatment on LDLR and LOX-1 expression
Twenty-four hour treatment of HMEC-1 with increasing doses of IL-6 (0, 0.1, 1, 10, 100 ng/ml) resulted in a significant increase of LDLR gene expression, with a maximal effect being observed at 1 ng/ml (p < 0.01, % increment versus control 63.47%, Fig. 3B ). Interestingly, LDLR gene expression after incubation with 10 ng/ml was found to be similar to the control; otherwise, a significant decrease in LDLR expression was observed when IL-6 100 ng/ml was added to HMEC-1 (p < 0.01, Fig. 3B ). IL-6 treatment resulted in a dose-dependent LOX-1 gene expression rise, increasing by 44.4%, 72.9%, 89.9% and 121.4% compared to the control, as shown in Fig. 3C .
DISCUSSION
In humans, the presence of high cholesterol levels is affected by many factors; among these LDLR is one of the most relevant. Minor variations of IL-6 serum levels are able to regulate LDLR [8] and consequently LDL plasma concentrations. As demonstrated by Gierens et al. [8] , IL-6 dose-dependently up-regulated the LDLR and consequently increased the binding, internalization, and degradation of LDL. Similarly, we found that this receptor as well as LOX-1 can be induced in endothelial cells following stimulation with IL-6. Accumulating evidence indicates that ox-LDL uptake through LOX-1 reduces nitric oxide production and activates NF-kB [17, 18] . Vascular inflammation and receptor up-regulation, events associated with atherosclerosis, represent important factors that improve the uptake of LDL and ox-LDL. This later mechanism of defense, induced by endothelium to reduce the presence in the circulation of LDL and lipoperoxides, cannot be sufficiently effective, and it introduces factors that contribute to the progression of atherosclerosis and to plaque instability [35] . The present in vitro model showed the effects of treatment with human LDL on the synthesis of IL-6. Cultured HMEC-1, in the presence of moderate to high levels of LDL and degree of oxidation, increased the expression of IL-6, with a consistent dose-related rise. The treatment with IL-6 induced evident up-regulation of LDLR and LOX-1. LDLR showed an initial increase that was reduced at the highest concentrations, returning to control values. A similar trend is attributable to a mechanism of down-regulation observed in many biological systems, when the concentration of a protein that normally stimulates the expression of a gene is elevated. A similar condition, in a different context, was observed in vivo the prolonged somministration of opioid agonists acted as a negative feedback modulator, down-regulating the expression of opioid receptors [36] . No studies have correlated this biphasic activity of IL-6 on the LDL-R, but this will be the next target of our investigations.
Indeed, one should bear in mind that the concentration of IL-6 evaluated with ELISA in healthy subjects ranged between 0 and 7 pg/ml, and in patients with coronary atherosclerosis IL-6 values can reach about 30 pg/ml [37] ; therefore it is very unlikely that such an effect on LDLR will be observed in vivo.
In the liver, the response to a similar stimulus would be the up-regulation of LDLR, with the consequent reduction of the serum cholesterol levels [8] . In metabolic disorders such as hypercholesterolemia, native LDL and vascular inflammation alter the reactive oxygen species generation, perturbing endothelial oxidative metabolism and uncoupling L-arginine metabolism from NO release to increase eNOS generation of O 2 -, inducing the mechanism of endothelial dysfunction and atherogenesis [38] . The enhanced generation of reactive oxygen species propagates the LDL oxidation and the formation of lipoperoxides such as 8-isoprostane. This metabolite was associated with oxidative stress damage and IL-6 levels in acute inflammation [39] . It was reported that 8-isoprostane performed its biological activity through interaction with the TXA 2 receptor [40] . 8-Isoprostane is considered a potent pulmonary and renal vasoconstrictor [26] . Therefore it has been proposed as a marker of antioxidant deficiency and oxidative stress [41] . In our study, we have demonstrated that IL-6 levels can be increased by ox-LDL but not by 8-isoprostane through its interaction with the TXA 2 receptor. These results suggest that 8-isoprostane does not affect the rise of LDL and ox-LDL induced IL-6. In summary, our data demonstrate a strong correlation between the concentration of IL-6 and both LDL and ox-LDL, in HMEC-1; additionally, high levels of this cytokine induced up-regulation of the receptors, especially LOX-1. At the highest IL-6 levels we observed a reduction of LDLR expression, but in the case of hypercholesterolemia most LDL is converted into ox-LDL by the presence of high levels of free radicals [42] ; therefore LOX-1 is particularly responsible for the reduction of LDL and ox-LDL from the blood. Its expression is induced by two factors: the increase of ox-LDL and the presence of inflammation. This biological mechanism could explain the rapid reduction of cholesterol during the acute phase of inflammatory disease, as the cell of the microcirculation is the most representative of the entire circulatory system. The mechanisms through which cholesterol acts on the onset of atherosclerosis are still poorly understood. This study seeks to shed light on the preliminary events of the disease so as to prevent damage induced by hypercholesterolemia. Our data indicate that endothelial cells trying to reduce the high plasma levels of native and oxidized LDL cholesterol cause injury of the endothelium. In our opinion, the employment of drugs reducing vascular inflammation or oxidant status could represent a good approach to reduce LOX-1 and LDLR expression that may become strongly associated with the health of arteries.
LIMITATION OF THE STUDY
Our study was performed using our in vitro cell model of human microvascular cells. Further studies will be focused on animal and human endothelial cells from arteries to investigate and confirm in vivo the same molecular interactions observed in vitro.
